Catalyst Biosciences (CBIO) Stock Price, News & Analysis

Company Overview

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.34 to $7.67
• 52-Week Range: N/A
• Volume: 32,246 shs
• Average Volume: 763,526 shs
• Market Capitalization: $291.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CBIO Stock Analysis - Frequently Asked Questions

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) posted its earnings results on Thursday, August, 17th. The biopharmaceutical company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07).

When did Catalyst Biosciences' stock split?

Shares of Catalyst Biosciences reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Biosciences investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• CUSIP: 87611R30
• CIK: 1124105
• Web: www.catalystbiosciences.com
• Phone: (650) 871-0761
• Fax: 336-480-2107
• Employees: 7
• Year Founded: 2003

Profitability

• EPS (Most Recent Fiscal Year): ($1.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,240,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -364.68%
• Return on Assets: -281.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 2.88

Sales & Book Value

• Annual Sales: $790,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.78) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 37,980,000
• Free Float: 36,869,000
• Market Cap: $291.29 million
• Optionable: Optionable
• Beta: 1.05